Winship Cancer Institute

Emory University

Atlanta, GA

Sorting 28 by

Accepting patients

QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
  • CAR T Cell
  • GPRC5D
  • Phase 2

Accepting patients

QUINTESSENTIAL-2

Phase 3 Clinical Trial Comparing the Safety and Efficacy of BMS-986393 to Standard of Care Regimens in Patients with Relapsed/Refractory Multiple Myeloma
  • CAR T Cell
  • GPRC5D
  • Randomization
  • Phase 3
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

EXCALIBER - Maintenance

Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma
  • CELMoD
  • Post-Autologous Stem Cell Transplant
  • Randomization
  • Phase 3

Not yet accepting

DREAMM-10

A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 3

Accepting patients

MonumenTAL-6

A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
  • Bispecific Antibody
  • CD3
  • GPRC5D
  • Randomization
  • Phase 3

Accepting patients

MonumenTAL-1

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
  • Bispecific Antibody
  • GPRC5D
  • Phase 2

Accepting patients

MagnetisMM-20

Phase 1B Study Evaluating Elranatamab in Combination with Carfilzomib/Dexamethasone or in Combination with PF-07901801 (maplirpacept) in Relapsed/Refractory Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Phase 1
  • Has results

Accepting patients

Personalized Autologous Transplant

Personalized Autologous Transplant for Multiple Myeloma
  • Autologous Stem Cell Transplant
  • Vaccine
  • Phase 1

Accepting patients

Venetoclax and Tocilizumab for t(11;14)

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
  • BCL-2 Inhibitor
  • Phase 1

Accepting patients

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
  • Autologous Stem Cell Transplant
  • CAR T Cell
  • BCMA
  • Phase 3
3 hidden based on your filters. Show All